Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies
- PMID: 23986586
- PMCID: PMC3807317
- DOI: 10.1128/JVI.01672-13
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3807317/bin/zjv9990982250001.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3807317/bin/zjv9990982250002.gif)
![Fig 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3807317/bin/zjv9990982250003.gif)
![Fig 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3807317/bin/zjv9990982250004.gif)
Similar articles
-
Antibodies and vaccines against Middle East respiratory syndrome coronavirus.Emerg Microbes Infect. 2019;8(1):841-856. doi: 10.1080/22221751.2019.1624482. Emerg Microbes Infect. 2019. PMID: 31169078 Free PMC article. Review.
-
Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.Emerg Microbes Infect. 2019;8(1):760-772. doi: 10.1080/22221751.2019.1620083. Emerg Microbes Infect. 2019. PMID: 31130102 Free PMC article.
-
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.Vaccine. 2017 Mar 14;35(12):1586-1589. doi: 10.1016/j.vaccine.2017.02.012. Epub 2017 Feb 23. Vaccine. 2017. PMID: 28237499 Free PMC article.
-
MERS-CoV spike protein: Targets for vaccines and therapeutics.Antiviral Res. 2016 Sep;133:165-77. doi: 10.1016/j.antiviral.2016.07.015. Epub 2016 Jul 26. Antiviral Res. 2016. PMID: 27468951 Free PMC article. Review.
-
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.J Virol. 2015 Aug;89(16):8651-6. doi: 10.1128/JVI.00614-15. Epub 2015 May 27. J Virol. 2015. PMID: 26018172 Free PMC article.
Cited by
-
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z. NPJ Vaccines. 2024. PMID: 38278816 Free PMC article.
-
The emergence of SARS-CoV-2 lineages and associated saliva antibody responses among asymptomatic individuals in a large university community.PLoS Pathog. 2023 Aug 21;19(8):e1011596. doi: 10.1371/journal.ppat.1011596. eCollection 2023 Aug. PLoS Pathog. 2023. PMID: 37603565 Free PMC article.
-
Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice.Pathogens. 2023 Jun 23;12(7):867. doi: 10.3390/pathogens12070867. Pathogens. 2023. PMID: 37513714 Free PMC article.
-
Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.Vaccines (Basel). 2023 May 21;11(5):1006. doi: 10.3390/vaccines11051006. Vaccines (Basel). 2023. PMID: 37243110 Free PMC article.
-
Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice.Vaccines (Basel). 2023 Mar 23;11(4):714. doi: 10.3390/vaccines11040714. Vaccines (Basel). 2023. PMID: 37112626 Free PMC article.
References
-
- Bermingham A, Brown MA, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R, Price N, Newsholme W, Drosten C, Fouchier RA, Zambon M. 2012. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to United Kingdom from the Middle East. Euro Surveill. 17:pii=20290 http://www.eurosurveillance.org/viewarticle.aspx?articleid=20290 - PubMed
-
- van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3(6):e00473–12.10.1128/mBio.00473-12 - DOI - PMC - PubMed
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RAM. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814–1820 - PubMed
-
- Chan JFW, Chan KH, Choi GKY, To KKW, Tse H, Cai JP, Yeung ML, Cheng VC, Chen H, Che XY, Lau SK, Woo PC, Yuen KY. 2013. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 207:1743–1752 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources